Skip to content
Test Spares Extended Endocrine Therapy In Low-Risk ER+ Breast Cancer

Test Spares Extended Endocrine Therapy In Low-Risk ER+ Breast Cancer

Get the podcast

CHICAGO—A gene test that predicts for relapse in women with estrogen receptor positive early breast cancer can identify patients with low-risk disease who could safely avoid extending their endocrine

The Audio Journal of Oncology

CHICAGO—A gene test that predicts for relapse in women with estrogen receptor positive early breast cancer can identify patients with low-risk disease who could safely avoid extending their endocrine therapy beyond the standard five years, according to study findings reported in a poster session at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Co-author Graham M Poage PhD, a scientist with the Biotheranostics Company based in La Jolla, California tells the Audio Journal of Oncology about the “Breast Cancer Index” (BCI) test—a reverse transcription polymerase chain reaction (RT-PCR) 11-gene assay—was an endocrine-therapy decision-making tool that had identified very low risk—patients who had 20-year breast cancer specific survival of 98 per cent—a significant proportion of patients who, potentially, could be spared extended endocrine therapy because their risk is so low that continued therapy is unlikely to benefit [them].

Tags

11 gene test for endocrine therapy needBiotheranosticsbreast-cancerER+ breast cancerGraham M PoageHR+ breast cancerlow-risk breast cancersparing extended endocrine therapy

Next in ASCO 2018

All 10 interviews

Interview 6 of 10

Superior Survival in Conservatively Treated Male Breast Cancer

Superior Survival in Conservatively Treated Male Breast Cancer

CHICAGO—Men who had breast-conserving therapy (BCT) including radiation for their early breast cancer lived longer than those who had total or partial mastectomy—with or without radiation—in findings

13 July 2018

Related Episodes

Eline Verreck BSc; 2026 EBCC: Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer

Eline Verreck BSc; 2026 EBCC: Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer

Radiation Boost May No Longer Be Justified After Standard Therapy for Early Breast Cancer An interview with: Eline Verreck BSc, Erasmus University Medical Centre, Surgical Oncology Department, Rotterd

6 Apr 2026
7 min